NWBO Northwest Biotherapeutics Inc

$NWBO $NWBO — Big Pharma is pouring billions into bispecific antibodies and ADCs, with Roche, Pfizer, AstraZeneca, Summit and others chasing the next oncology breakthrough. Yet one of the most intriguing immunotherapy combinations remains largely overlooked: DCVax-L + Merck’s Keytruda in recurrent GBM, one of the toughest cancers to treat! Early UCLA results suggest potentially remarkable survival improvements, with reported median survival more than doubling historical expectations. Unlike targeted mRNA vaccines focusing on selected antigens, DCVax-L uses whole-tumor lysate to expose the immune system to a broad spectrum of tumor antigens. Imagine combining that personalized immune response with checkpoint inhibition! Moderna/Merck’s melanoma vaccine combination is promising, but NWBO’s approach deserves serious attention. Early-stage, yes—but potentially a major contender in the next generation of cancer immunotherapy!

$NWBO Todays my birthday (70). I bought another 5000 shares to celebrate. As I know it be worth 10 times that soon!

$NWBO It’s looking more and more like Linda swung for the fences and hit out of the park. They have all but told us approval is coming and for all solid tumors, who woulda thunk. What’s next? Saudi is coming on board maybe finalized in November. Project Orbis? Maybe Which of the big pharmas want a piece of the oncology pie. I can’t wait to find out. Whatever happens I’m here for it. Let’s get it fam.

$NWBO I believe the NHS news was the MOST SIGNIFICANT POSITIVE DEVELOPMENT in NWBO’s history, and shorts & MMs are scrambling behind the scenes. While the continued dilution at all time low prices hasn’t done shareholders any favors, I’m fairly certain today’s 1.4 MILLION-SHARE TRADE JUST AFTER CLOSING had nothing to do with dilution. I believe the nearly 20 MILLION SHARES TRADED ON EACH OF THE LAST TWO DAYS largely reflect retail buying following the NHS news, while shorts and market makers are using algorithmic trading to relentlessly pound the price down and PREVENT A SQUEEZE. My suspicion is that shorts are opening positions throughout the day to suppress the price, then COVERING THROUGH LARGE TRADES REPORTED SECONDS AFTER CLOSING without driving the price back up. If that’s what’s happening, it’s BLATANT MANIPULATION AND FRAUD. I hope MHRA approval finally burns these bastards.

$NWBO Dr Chalmers is paid handsomely by big pharma. So he is biased and compromised without a doubt as far as DCVax is concerned. The good news is he is not working for MHRA, he is not on their board. Could he have some influence? Maybe, possibly but let me tell you who has a helluva lot more influence in the UK’s medical circles, Dr. Jankins. So should there be panic in the streets? Absolutely not.The DCVax train is to far down the tracks to be stopped, big pharma be dammed. Of course this is just my humble opinion and I don’t know Jack or his brother sh*t.

$NWBO It would be beautiful if MHRA could come up with the approval, and sort of nip it the bud before the government’s henchman gets involved. After all. MHRA does not need any government permission . This week would be just fine.Just wishing.

$NWBO $NWBO — Could tomorrow be the day shorts get caught completely off guard? After this long wait for the MHRA decision on DCVax-L, UK approval news could arrive when the market least expects it! Strugat reportedly spotted unusual 75K trading volume today. Is someone positioning ahead of a catalyst, or just coincidence? Nobody knows! Between the pending UK regulatory decision, Saudi opportunities, and Judge Stein’s awaited ruling on algorithm discovery, the potential catalysts are enormous. Imagine an unexpected MHRA approval announcement before tomorrow’s opening bell! FOMO among buyers and pressure on shorts to cover could make for an explosive combination. Pure speculation, but after years of patience, longs have plenty of reasons to watch closely!

$NWBO celebrating my birthday today! Though my wish of approval did not come to pass by this special day, I continue to wish upon a star. 💫 🙏🏽🧘🏻‍♀️🕯🗝

$NWBO Word of the day : “Don’t lend your shares to short sellers. You earn a few pennies while helping them increase selling pressure, suppress the share price, and undermine your own investment. Don’t finance your own opposition!” Also, don’t set stop losses if you are a genuine Long. They can be seen by everyone on Level 2 and will be wiped out !

$NWBO MHRA authorities are independent from the Prime Minister’s Office meaning the approval process doesn’t depend on the PM’s initiative and will keep moving as it pleases. Therefore, it is reasonable to assume that a decision is coming soon. Either, they tell NWBO to pack their bags and move back to Maryland or open shop and give a chance at life to the thousands of cancer patients who have been waiting for too long for this to occur. Either way they will have to do something and move on to other priorities. Same story for Judge Stein : drop the hammer because not doing so is a waste of everyone’s time and efforts.

$NWBO I have no idea if Braelyn and Amanda will get to meet President Trump on Wednesday or not. But how awesome would it be if they did.

$NWBO $NWBO — 6.8M shares in the first hour, up over 10%, touching $0.1749! Momentum is accelerating! Level II shows relatively light asks near current prices, with MACD turning bullish and RSI climbing. Even more exciting, Dr. Andrew Caravello reportedly contacted NHSBT about whether expanding leukapheresis centers would support compassionate use or future MHRA-approved treatment. Reported answer: BOTH! As confirmed, that’s an encouraging signal of preparations for broader patient access. Could 20M+ shares trade today? If buying pressure continues and resistance falls, $0.20 could come into play sooner than expected! The combination of manufacturing readiness, regulatory anticipation and rising volume is getting very interesting. Longs, stay tuned!

$NWBO Here's what AI thinks of the NWBO collaboration announced in the new trial news posted publicly: NWBO is being integrated into cutting‑edge dendritic cell immunotherapy science They are collaborating on a Keytruda‑inclusive Phase 2 trial They are expanding beyond GBM They are being recognized by academic leaders They are positioning themselves as a DC platform company They are preparing for post‑approval life The dilution is tied to strategic growth, not desperation This is exactly the kind of move that foreshadows good financing news.

$NWBO Whilst some find conflict of interest in recently appointed Commissioner, I remind that NWBO and NHSBT have announced that they have entered into a collaboration, as the culmination of months of joint efforts by the parties, to support production of the Company’s experimental cancer vaccine DCVax®-L. Looking forward to hear Dr. Liau’s debrief on the combo in Ovarian this Sunday. Have a great weekend! and remember: 💎 🙌 HODL MOASS 💯 Focus on the facts, not on the noise.

$NWBO Shorty is desperate. IBKR just offered me to lend out my shares for more than ten percent of SP a year! Insanely desperate.

$NWBO Should be .50 cents to a dollar already was it not for Citadell and Virtu Hope thes actors choke on their own food

$NWBO I support this letter. At the very least Dr. Chalmers needs to be put on notice that we know about his background. If you are a long term shareholder who has suffered through the many attacks over the years, we cannot give up. We must keep fighting.

$NWBO Hopefully the Next New News will be Approval until that time Like the A$$ bite kenny G says retail will never beat my systems or MM cant wait to prove that POS wrong ! GLTA

$NWBO PT 5 “The hypothetical scenario where NWBO uses Catalent’s Princeton-to-France pipeline wouldn’t be to replace Sawston, but rather to establish a highly structured global redundancy and dual-sourcing model. While the Sawston facility (via Advent BioServices) is firmly positioned as the central hub for the UK and primary European supply, relying on a single manufacturing site for a commercial, life-saving oncology drug introduces a massive business risk 1. De-Risking the Supply Chain (Dual Sourcing) In commercial pharmaceutical manufacturing, regulatory agencies like the FDA and EMA heavily favor companies that have a "dual-source" strategy. If Sawston ever experiences a temporary operational shutdown, power failure, or local regulatory bottleneck, global distribution of DCVax-L could completely halt. Having Catalent's Princeton facility validated to manufacture the drug—with an active, pre-vetted transit route through Limoges, France—gives NWBO a multi-continental backup line.”

$NWBO IMO the new developments over the past week or so, including today clearly point to NWBO becoming a respected DC (dendritic Cell) Platform Company. While my dilution fears still exist, they have been significantly mitigated. The past week and the month to come will be seen as An Historic Turning Point for NWBO and its shareholders. Partnerships, Grants etc...are now in the Pipeline, not just pipe dreams.